FDA approves Tecentriq for adjuvant muscle-invasive bladder cancer with ctDNA-guided treatment
May 16, 2026
The FDA approved Tecentriq and Tecentriq Hybreza for adjuvant muscle-invasive bladder cancer with ctDNA molecular residual disease after cystectomy. The Phase III IMvigor011 study showed a 36% reduction in recurrence or death and a 41% reduction in death.